With Big Pharma mergers in the works, whose SG&A costs look ripe for cutting?

With Big Pharma mergers in the works, whose SG&A costs look ripe for cutting?

Submitted by admin on April 30, 2014 - 1:10pm
Source: 
Fierce Pharma Marketing
News Tags: 
layoffs
M&A
Novartis
GSK
Pfizer
AstraZeneca
Headline: 
With Big Pharma mergers in the works, whose SG&A costs look ripe for cutting?

Do Not Allow Advertisers to Use My Personal information